Scarica l'app Stockscreener
1.89
3.08%
-0.06
Dopo l'orario di chiusura:
1.86
-0.03
-1.59%
Inhibikase Therapeutics Inc Borsa (IKT) Ultime notizie
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to "Strong-Buy" at LADENBURG THALM/SH SH - MarketBeat
Inhibikase Therapeutics (IKT) Gains New Coverage with 'Buy' Rati - GuruFocus
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Update - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Coverage Initiated at LADENBURG THALM/SH SH - MarketBeat
Ladenburg Thalmann Initiates Inhibikase Therapeutics at Buy - marketscreener.com
Athira Pharma (NASDAQ:LONA) versus Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Analysis - Defense World
FY2025 Earnings Forecast for IKT Issued By Lifesci Capital - Defense World
IKT Should I Buy - Intellectia AI
A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress - simplywall.st
Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4%Still a Buy? - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4% – Still a Buy? - Defense World
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded by Lifesci Capital to "Strong-Buy" Rating - MarketBeat
Analyzing Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
IKT Stock Surge: What’s Driving the 13% Jump Today? - Creative Learning Guild
Inhibikase (IKT) R&D president forfeits 338,282 milestone-based shares - Stock Titan
Inhibikase (IKT) director Amit Munshi forfeits 19,089 milestone-based shares - Stock Titan
IKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IKT Stock Bounces Amid Steady Growth Potential - StocksToTrade
Inhibikase Therapeutics: A Surge in Market Interest on Recent Developments - timothysykes.com
IKT Surges Amid Strategic Developments and Market Shifts - StocksToTrade
Inhibikase Therapeutics Stock Faces Challenges Amid Financial Uncertainty - timothysykes.com
Certain Warrants of Inhibikase Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-FEB-2026. - marketscreener.com
ADAR1 group discloses 9.9% Inhibikase (IKT) ownership via shares and warrants - Stock Titan
Fairmount discloses 9.9% Inhibikase (IKT) stake via shares and warrants - Stock Titan
Will Inhibikase Therapeutics Inc. stock deliver consistent dividendsMarket Sentiment Review & Technical Buy Zone Confirmations - mfd.ru
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
[SCHEDULE 13G/A] Inhibikase Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Does Inhibikase Therapeutics Inc. stock benefit from AI growthChart Signals & Free Expert Approved Momentum Trade Ideas - mfd.ru
Inhibikase Therapeutics (NASDAQ:IKT) Trading Up 6.9%Time to Buy? - MarketBeat
Aug Big Picture: Can Inhibikase Therapeutics Inc sustain its profitability2025 Valuation Update & Entry Point Confirmation Signals - baoquankhu1.vn
What’s next for Inhibikase Therapeutics Inc. stockWeekly Profit Recap & High Conviction Investment Ideas - mfd.ru
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Pfizer (PFE) and Inhibikase Therapeutics (IKT) - The Globe and Mail
Aug Chart Watch: Is Inhibikase Therapeutics Inc a potential multi baggerJuly 2025 WrapUp & Target Return Focused Stock Picks - baoquankhu1.vn
Guidance Update: Is Precision Drilling Corporation affected by consumer sentimentEarnings Overview Summary & Weekly High Potential Alerts - baoquankhu1.vn
Risk Report: Does Inhibikase Therapeutics Inc stock benefit from AI growth2025 Market Outlook & Smart Investment Allocation Insights - baoquankhu1.vn
Market Outlook: Is HCA Healthcare Inc stock a smart retirement pickJuly 2025 Movers & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
What drives Inhibikase Therapeutics Inc.’s stock priceQuarterly Trade Report & Short-Term High Return Ideas - mfd.ru
B of A Securities Initiates Coverage of Inhibikase Therapeutics (IKT) with Buy Recommendation - Nasdaq
BofA Securities initiates coverage on Inhibikase stock with Buy rating By Investing.com - Investing.com South Africa
Inhibikase Therapeutics (NYSE:IKT) Earns Buy Rating from Analysts at Bank of America - MarketBeat
B of A Securities Initiates Coverage on IKT with 'Buy' Rating | - GuruFocus
BofA Securities initiates coverage on Inhibikase stock with Buy rating - Investing.com
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
What analyst consensus says on Inhibikase Therapeutics Inc. stockQuarterly Profit Report & Expert Curated Trade Ideas - Bollywood Helpline
Can Inhibikase Therapeutics Inc. stock sustain free cash flow growthMarket Growth Report & Daily Stock Momentum Reports - bollywoodhelpline.com
RSI Check: Does Inhibikase Therapeutics Inc outperform in volatile marketsMarket Growth Report & High Accuracy Investment Signals - baoquankhu1.vn
Inhibikase Therapeutics (NYSE:IKT) Trading Up 1.2%What's Next? - MarketBeat
Take Profit: Why Inhibikase Therapeutics Inc stock could outperform in 2025 - Bộ Nội Vụ
Published on: 2026-01-14 00:17:08 - Bộ Nội Vụ
How Inhibikase Therapeutics Inc IQT0 stock reacts to stronger dollarSwing Trade & Growth Focused Investment Plans - Bộ Nội Vụ
Why Inhibikase Therapeutics Inc. stock attracts global investorsBest Sellers Snapshot & trail grip notes for mixed terrain - Улправда
How Inhibikase Therapeutics Inc. stock performs in weak economyMarket Weekly Review & Technical Entry and Exit Tips - Улправда
Is Inhibikase Therapeutics Inc. stock attractive for passive investorsPortfolio Update Report & Weekly Watchlist of Top Performers - ulpravda.ru
Can Inhibikase Therapeutics Inc. stock sustain institutional interestJuly 2025 PostEarnings & Stepwise Trade Execution Plans - Улправда
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):